Literature DB >> 27047631

Onychomycosis of Toenails and Post-hoc Analyses with Efinaconazole 10% Solution Once-daily Treatment: Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes.

James Q Del Rosso1.   

Abstract

Topical treatment for toenail onychomycosis has been fraught with a long-standing reputation of poor efficaey, primarily due to physical properties of the nail unit that impede drug penetration. Newer topical agents have been formulated as Solution, which appear to provide better therapeutic response in properly selected patients. It is important to recognize the impact the effects that mitigating and concomitant factors can have on efficaey. These factors include disease severity, gender, presence of tinea pedis, and diabetes. This article reviews results achieved in Phase 3 pivotal studies with topical efinaconazole 10% Solution applied once daily for 48 weeks with a focus on how the aforementioned factors influenced therapeutic outcomes. It is important for clinicians treating patients for onychomycosis to evaluate severity, treat concomitant tinea pedis, address control of diabetes if present by encouraging involvement of the patient's primary care physician, and consider longer treatment courses when clinically relevant.

Entities:  

Year:  2016        PMID: 27047631      PMCID: PMC4771389     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  33 in total

1.  Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey.

Authors:  A K Gupta; N Konnikov; P MacDonald; P Rich; N W Rodger; M W Edmonds; R McManus; R C Summerbell
Journal:  Br J Dermatol       Date:  1998-10       Impact factor: 9.302

Review 2.  Fungal infections in HIV-infected patients.

Authors:  F M Durden; B Elewski
Journal:  Semin Cutan Med Surg       Date:  1997-09

3.  Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients.

Authors:  Jacek C Szepietowski; Adam Reich; Emilia Garlowska; Marzena Kulig; Eugeniusz Baran
Journal:  Arch Dermatol       Date:  2006-10

4.  Effect of onychomycosis on quality of life.

Authors:  L A Drake; R K Scher; E B Smith; G A Faich; S L Smith; J J Hong; M J Stiller
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

5.  Onychomycosis: a significant medical disorder.

Authors:  R K Scher
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

6.  Efinaconazole Topical Solution, 10%: Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis.

Authors:  Bryan C Markinson; Bryan D Caldwell
Journal:  J Am Podiatr Med Assoc       Date:  2015-04-13

Review 7.  The prevalence and management of onychomycosis in diabetic patients.

Authors:  A K Gupta; S Humke
Journal:  Eur J Dermatol       Date:  2000 Jul-Aug       Impact factor: 3.328

8.  Onychomycosis: current treatment options.

Authors:  Ellen Davis Jones
Journal:  J Am Acad Nurse Pract       Date:  2003-04

9.  Distribution of toenail dystrophy predicts histologic diagnosis of onychomycosis.

Authors:  Hobart W Walling; Patrick J Sniezek
Journal:  J Am Acad Dermatol       Date:  2007-03-26       Impact factor: 11.527

10.  Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10.

Authors:  Ted Rosen
Journal:  Cutis       Date:  2015-09
View more
  1 in total

1.  More than Nail Deep: The Effect of Efinaconazole 10% Treatment on the Quality of Life in Patients with Onychomycosis: A post hoc Study.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Emma M Quinlan; Madhulika A Gupta; Naveen Anbalagan; Rachel Lyons
Journal:  Skin Appendage Disord       Date:  2021-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.